SCHEMBL3426757

SCHEMBL3426757

Cc1c(-c2cccs2)nc2ccc(-c3ccc(F)[c]c3F)cn12

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 11/20 0.41
▸ TP53 P04637 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ GABRD O14764 2/20 0.36
▸ GABRB1 P18505 2/20 0.36
▸ GABRA4 P48169 2/20 0.36
▸ SLC2A1 P11166 1/20 0.35
▸ CYP11B1 P15538 3/20 0.35
▸ CYP11B2 P19099 3/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431629 0.77 NR4A2 (0.46) NR1H4TP53GAAGABRDGABRB1
SCHEMBL3430234 0.76 NR1H4 (0.41) NR1H4TP53GAAGABRDGABRB1
SCHEMBL3435404 0.72 NR1H4 (0.36) NR1H4TP53GAAGABRDGABRB1
SCHEMBL3435401 0.71 NR1H4 (0.34) NR1H4TP53GAAGABRDGABRB1
SCHEMBL219497 0.71 NR1H4 (0.42) NR1H4TP53GAAGABRDGABRB1
Hydrochloric Acid SCHEMBL6521449 0.71 NR1H4 (0.52) NR1H4TP53GAAGABRDGABRB1
SCHEMBL218008 0.70 NR1H4 (0.43) NR1H4TP53GAAGABRDGABRB1
SCHEMBL3429663 0.70 NR1H4 (0.53) NR1H4TP53GAAGABRDGABRB1
SCHEMBL220518 0.70 NR1H4 (0.45) NR1H4TP53GAAGABRDGABRB1
SCHEMBL3409535 0.69 CYP11B1 (0.46) NR1H4TP53GAAGABRDGABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 — — EP disclosed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 — — WO disclosed
Send feedback